KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Short-term Investments: 2018-2022

Historic Short-term Investments for Esperion Therapeutics (ESPR) over the last 4 years, with Dec 2022 value amounting to $42.1 million.

  • Esperion Therapeutics' Short-term Investments fell 74.42% to $17.4 million in Q1 2023 from the same period last year, while for Mar 2023 it was $17.4 million, marking a year-over-year decrease of 74.42%. This contributed to the annual value of $42.1 million for FY2022, which is 16.56% down from last year.
  • According to the latest figures from FY2022, Esperion Therapeutics' Short-term Investments is $42.1 million, which was down 16.56% from $50.4 million recorded in FY2021.
  • Esperion Therapeutics' Short-term Investments' 5-year high stood at $99.0 million during FY2018, with a 5-year trough of $34.7 million in FY2019.
  • Moreover, its 2-year median value for Short-term Investments was $46.3 million (2021), whereas its average is $46.3 million.
  • Data for Esperion Therapeutics' Short-term Investments shows a maximum YoY slumped of 65.02% (in 2019) over the last 5 years.
  • Esperion Therapeutics' Short-term Investments (Yearly) stood at $99.0 million in 2018, then slumped by 65.02% to $34.7 million in 2019, then reached $50.4 million in 2021, then dropped by 16.56% to $42.1 million in 2022.